Optimum treatment of stable angina pectoris

Cardiovascular Drugs and Therapy

Volumn 12, Issue SUPPL. 1, 1998, Pages 105-110

  Parmley, William W ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UCSF Medical Center at Parnassus   (United States)

Author keywords

Angina pectoris; Beta blockers; Calcium blockers; Endothelial function; Nitrates

Indexed keywords

ANGINA PECTORIS; EXERCISE; FEMALE; HUMAN; MALE; REVIEW; BLOOD PRESSURE; CONFERENCE PAPER; CORONARY ARTERY BLOOD FLOW; HEART LEFT VENTRICLE MASS; HEART MUSCLE OXYGEN CONSUMPTION; HEART RATE; HEART SIZE; ISRAEL; OXYGEN SUPPLY; PRIORITY JOURNAL; RISK FACTOR; SYMPOSIUM; VASCULAR ENDOTHELIUM; VASODILATATION;

ANGINA PECTORIS; EXERCISE; FEMALE; HUMANS; MALE;

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CORONARY VASODILATING AGENT; DIHYDROPYRIDINE DERIVATIVE; NITRATE;

EID: 0032036892     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1023/a:1007736027416     Document Type: Article

References (40)

1. Karliner JS. Coronary artery bypass surgery. Parmley WW, Chatterjee K, eds. Cardiology. Philadelphia: J.B. Lippincott, 1994, chap. 2-17.
2. Rogers WJ, Bourassa MG, Andrews TC, et al. for the ACIP Investigators. Asymptomatic Cardiac Ischemia Pilot (ACIP) study: Outcome at 1 year for patients with asymptomatic cardiac ischemia randomized to medical therapy or revascularization. J Am Coll Cardiol 1995;26:544-605.
3. von Arnim T, et al. Prognostic significance of transient ischemic episodes: Response to treatment shows improved prognosis. J Am Coll Cardiol 1996;28:20-24.
4. Pepine CJ, Cohn PF, Deedwania PC, et al. Effects of treatment on outcome in mildly symptomatic patients with ischemia during daily life. The Atenolol Silent Ischemia study (ASIST). Circulation 1994;90:762-768.
5. Parmley WW. Silent ischemia: Should the asymptomatic patient be treated? Card Rev 1993;1:67-76.
6. Vita JA, Treasure CB, Nabel EG, et al. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation 1990;81:491-497.
7. Nygard O, Vollset SE, Refsum H, et al. Total plasma homo-cysteine and cardiovascular risk profile. The Hordaland homocysteine study. JAMA 1995;274:1526-1533.
8. Rosano GMC, Peters NS, Lefroy D, et al. 17-beta estradiol therapy lessens angina in postmenopausal women with syndrome x. J Am Coll Cardiol 1996;28:1500-1506.
9. Mancini GBJ, Henry GC, Macaya C, et al. Angiotensin converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND Study. Circulation 1996;94:258-265.
10. Holzman S, Kukovetz WR, Windischofer W, Paschke E, Graier WF. Pharmacologic differentiation between endothelium dependent relaxation sensitive and resistant to nitro-1-arginine in coronary arteries. J Cardiovasc Pharmacol 1994;23:747-756.
11. van Boven ADJ, Jukema JW, Zwinderman AH, Crijns HSGM, Lie KI, Bruyschke AVG. Reduction of transient myocardial ischemia with pravastatin in addition to the conventional treatment with angina pectoris. Circulation 1996; 94:1503-1505.
12. van der Zee R, Murohara T, Luo Z, Zollman F, Passeri J, Lekutat C, Isner JM. Vascular endothelial growth factor/vascular permeability factor augments nitric oxide release from quiescent rabbit and human vascular endothelium. Circulation 1997;95:1030-1037.
13. Vogel RA. Comparative clinical consequences of aggressive lipid management, coronary angioplasty and bypass surgery in coronary artery disease.
14. Blomquist CG. Physiology and pathophysiology of exercise. In: Parmley WW, Chatterjee K, eds. Cardiology. Philadelphia: J.B. Lippincott, 1994.
15. Frishman WH, Pepine CJ, Weiss RJ, Baiker WM. Addition of zatebradine, a direct sinus node inhibitor, provides no greater exercise tolerance benefit in patients with angina taking extended release nifedipine: Results of a multicenter, randomized, double-blind, placebo-controlled, parallel group study. J Am Coll Cardiol 1995;26:305-312.
16. Massie BM. Hypertensive left ventricular hypertrophy: Pathophysiology and response to therapy. In: Parmley WW, Chatterjee K, eds. Cardiology. Philadelphia: J.B. Lippincott, 1992.
17. Schmieder RE, Martus P, Klingbell A. Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. JAMA 1996; 275:1507-1513.
18. Parmley WW, Nesto R, Singh BN, Deanfield J, Gottlieb SO, and the N-CAP Study Group. Attenuation of the circadian patterns of myocardial ischemia with nifedipine GITS in patients with chronic stable angina. J Am Coll Cardiol 1992; 19:1380-1389.
19. Fox KM, Mulcahy D, Findlay I, Ford I, Dargie HJ. The Total Ischemic Burden European Trial (TIBET). Effects of atenolol, nifedipine SR, and their combination on the exercise test and the total ischemic burden in 608 patients with stable angina. The TIBET Study Group. Eur Heart J 1996; 17:96-103.
20. Walker JM, Curry PVL, Bailey AE, Steare SE. Comparison of nifedipine once daily (Adalat LA), isosorbide mononitrate once daily and isosorbide dinitrate twice daily in patients with chronic stable angina. Int J Cardiol 1996;53:117-126.
21. Pepine CJ, Lopez LM, Bell DM, et al. Effects of intermittent transdermal nitroglycerin on occurrence of ischemia after patch removal: Results of the Second Transdermal Intermittent Dosing Evaluation Study (TIDES-II). J Am Coll Cardiol 1997;30:955-961.
22. de Vries, BJM, van den Heuvel Ad FM, Lok DJA, et al. Nifedipine gastrointestinal therapeutic system versus atenolol in stable angina pectoris. Int J Cardiol 1996;57: 143-150.
23. Ronnevik PK, Silke B, Ostergaard O. Felodipine in addition to beta adrenergic blockade for angina pectoris, a multicenter, randomized, placebo-controlled trial. Eur Heart J 1995; 16:1535-1541.
24. Hansen JF, Hagerup L, Sigurd B, et al. Cardiac event rates after acute myocardial infarction in patients treated with verapamil and trandolapril versus trandolapril alone. Am J Cardiol 1997;79:738-741.
25. Andrews TC, Fenton T, Toyasaki N, et al. Subsets of ambulatory myocardial ischemia based on heart rate activity. Circadian distribution and response to anti-ischemic medication. Circulation 1993;88:92-100.
26. Ardissino D, Savonitto S, Zanini P, et al. Ability of calcium entry blockade by felodipine to disclose different pathogenetic mechanisms behind hyperventilation induced myocardial ischemia in men. Am J Cardiol 1990;66:1304-1308.
27. Alpert JS, Kobrin I, DeQuattro V, et al. Additional antianginal and anti-ischemic efficacy of mibefradil in patients pretreated with a beta blocker for chronic stable angina pectoris. Am J Cardiol 1997;79:1025-1030.
28. Davies RF, Habibi H, Klinke WP, et al. Effect of amlodipine, atenolol and their combination on myocardial ischemia during treadmill exercise and ambulatory monitoring. J Am Coll Cardiol 1995;25:619-625.
29. Madjlessi-Simon T, Mary-Krause M, Fillette F, Lechat P, Jaillon F. Persistent transient myocardial ischemia despite beta adrenergic blockade predicts a higher risk of adverse cardiac events in patients with coronary artery disease. J Am Coll Cardiol 1996;27:1586-1591.
30. Antiplatelet Trialists Collaboration. Collaborative overview of randomized trials of antiplatelet treatment. Part I. Prevention of vascular death, MI, and stroke by prolonged antiplatelet therapy in different categories of patients. Br Med J 1994;308:81-106.
31. Hung J, Lamb IH, Connolly SJ, et al. The effect of diltiazem and propranolol, alone and in combination, on exercise performance and left ventricular performance and left ventricular function in patients with stable effort angina: A double-blind, randomized, and placebo-controlled study. Circulation 1983;68:560-567.
32. Meyer TE, Adnams C, Commerford P. Comparison of the efficacy of atenolol and its combination with slow-release nifedipine in chronic stable angina. Cardiovasc Drugs Ther 1993;7:909-913.
33. El-Tamimi A, Davies GJ, Optimal control of myocardial ischaemia: The benefit of a fixed combination of atenolol and nifedipine with chronic stable angina. Br Heart J 1992;68: 291-295.
34. Johnston DL, Lesoway R, Human DP, Kostuk WJ. Clinical and hemodynamic evaluation of propranolol in combination with verapamil, nifedipine, and diltiazem in exertional angina pectoris: A placebo-controlled, double-blind, randomized, crossover study. Am J Cardiol 1985;55:680-687.
35. Uusitalo A, Arstila M, Bae BA, et al. Metoprolol, nifedipine and the combination in stable effort angina pectoris. Am J Cardiol 1986;57:733-737.
36. Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995;274:620-625.
37. Furberg CD, Psaty BM, Meyer JV. Nifedipine: Dose related increase in mortality in patients with coronary artery disease. Circulation 1995;92:1326-1331.
38. Opie LH, Messerli RH. Nifedipine and mortality-grave defects in the dossier. Circulation 1995;92:1068-1073.
39. Furberg CD, Psaty BM. Corrections to the nifedipine meta-analysis. Circulation 1996;93:1475-1476.
40. The Danish Study Group on Verapamil in Myocardial Infarction. Effect of verapamil on mortality and major events after acute myocardial infarction (DAVIT II). Am J Cardiol 1990;66:779-785.